Pharmalucence Builds New Drug Production Facility in Massachusetts
06/04/2010
"Pharmalucence has long maintained a strong radiopharmaceutical business in Massachusetts," said Glenn Alto, president and CEO of Pharmalucence. "We are investing to fully replace and modernize our infrastructure to ensure we maintain our local presence going forward."
The investment was aided by a $20 million bond issued by MassDevelopment, the first use of the Recovery Zone Facility Bond program in the state. The bond is one component of the American Recovery and Reinvestment Act to stimulate the economy with low-cost financing.
Pharmalucence produces eight drugs to treat cancers and heart disease. Construction on the new facility will begin this summer, and the plant is expected to be operational by the end of 2012.
Project Announcements
United Arab Emirates-Based Hotpack Plans Edison, New Jersey, Manufacturing Operations
05/12/2025
SSAB Expands Axis, Alabama, Production Operations
05/12/2025
Carnival Corporation Plans Miami, Florida, Headquarters Operations
05/12/2025
Merck Animal Health Expands De Soto, Kansas, Manufacturing Operations
05/12/2025
Oxford Technologies Plans Bay County, Florida, Manufacturing Operations
05/12/2025
PPG Plans Shelby, North Carolina, Manufacturing Operations
05/12/2025
Most Read
-
Run a Job Task Analysis
Q4 2024
-
39th Annual Corporate & 21st Annual Consultants Surveys: What Business Leaders and Consultants Are Saying About Site Selection
Q1 2025
-
The Location Economics of Advanced Nuclear
Q1 2025
-
Why Workforce Readiness Can’t Wait
Q1 2025
-
Is It Time to Start Planning for Quantum Data Centers?
Q1 2025
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
Navigating the new era of SCIF construction
Q1 2025